Indegene Q1 Results FY27: Net Profit at Rs 116 Cr for June 2026 Quarter

Key Takeaways

• Indegene's revenue for the June 2026 quarter came in at Rs 1,063 Cr, rose 39.73% year on year from Rs 760 Cr.
• Indegene came in at a consolidated net profit of Rs 116 Cr, down 0.17% from Rs 116 Cr in Q1 FY26.
• Gross profit was reported at Rs 130 Cr for the quarter.
• The stock traded at Rs 514.7 on 30 July 2026, down 1.70% during the session.

If you are searching for Indegene Q1 results FY27, here is the direct answer: Indegene reported consolidated revenue of Rs 1,063 Cr and a net profit of Rs 116 Cr for the quarter ended 30 June 2026, rose 39.73% year on year from Rs 760 Cr. The rest of this article expands on that answer with the full revenue and profit breakdown, what changed compared with Q1 FY26, how the stock reacted, and what to watch next, so you do not need to piece it together from multiple sources.

Prepared by Kunal Singla, Associate Director at Univest, this review of the Indegene Q1 results FY27 is based on figures disclosed in the company's exchange filing for the June 2026 quarter.

Click Here – Get Free Investment Predictions

Indegene Q1 Results FY27: Key Numbers at a Glance

Metric	Q1 FY27	Q1 FY26	YoY Change
Revenue	Rs 1,063 Cr	Rs 760 Cr	39.73%
Gross Profit	Rs 130 Cr	Rs 133 Cr	-2.69%
Net Profit	Rs 116 Cr	Rs 116 Cr	-0.17%

All figures in the Indegene Q1 results FY27 table above are on a consolidated basis for the quarter ended 30 June 2026, compared with Q1 FY26. This is the core data set behind the Indegene Q1 results FY27 search.

Indegene Q1 Results FY27: What Drove Revenue

Revenue for Indegene in Q1 FY27 rose 39.73% from Rs 760 Cr to Rs 1,063 Cr, against Rs 760 Cr in Q1 FY26. Anyone comparing Indegene against its own past performance should treat this as the base number: a company in the healthcare digital technology and consulting space, this pace of growth reflects demand and pricing trends specific to that segment during the June 2026 quarter.

Indegene Q1 Results FY27: Profitability Breakdown

Indegene came in at a consolidated net profit of Rs 116 Cr, down 0.17% from Rs 116 Cr in Q1 FY26 in Q1 FY27. Gross profit for the quarter was Rs 130 Cr, a change of -2.69% from Rs 133 Cr in Q1 FY26.

The broadly consistent movement between gross profit and net profit in the Indegene Q1 results FY27 suggests the quarter's profit performance is being driven mainly by core operations rather than one-off or below-the-line items.

Stock Price Reaction to the Indegene Q1 Results FY27

Indegene shares traded at Rs 514.7 on 30 July 2026, down 1.70% during the session. If your search intent is specifically about the stock reaction rather than the raw numbers, this is the figure that answers it: the market's verdict weighed the revenue and profit results together, alongside broader market conditions on the day.

Talk to a SEBI Registered Investment Adviser Before You Invest

What the Indegene Q1 Results FY27 Mean for Investors

The Indegene Q1 results FY27 give investors three concrete data points: a revenue base of Rs 1,063 Cr, a net profit of Rs 116 Cr, and a year-on-year growth trajectory that either confirms or challenges the investment thesis for the stock. None of these numbers should be read in isolation from the detailed exchange filing, segment disclosures and management commentary that typically accompany results.

Comparing this quarter with peers in the healthcare digital technology and consulting space is also useful context. A company can post strong absolute growth and still lag its peer set, or post modest growth that is nonetheless best-in-class for its sector, so relative positioning matters as much as the standalone numbers in the Indegene Q1 results FY27. Investors who track a basket of names in the same industry will typically get a clearer read on whether this quarter reflects a company-specific story or a broader sector trend.

Business Context Behind the Indegene Q1 Results FY27

Indegene operates in the healthcare digital technology and consulting space, where demand cycles, input costs and competitive intensity all shape quarterly performance. The Indegene Q1 results FY27 should be read against these sector-level dynamics rather than as a standalone number, since the same growth rate can carry very different implications depending on the underlying industry conditions.

Quarterly results are unaudited and subject to limited review, so any restatements or exceptional items disclosed in the notes to the Indegene Q1 results FY27 can shift how the reported profit should be interpreted. Reading the full exchange filing alongside this summary remains the most reliable way to form a complete view, particularly for line items such as other income, exceptional items and tax adjustments that do not always show up in a headline summary.

Key Things to Watch After the Indegene Q1 Results FY27

• Sequential trend: Whether the momentum in the Indegene Q1 results FY27 carries into the September 2026 quarter or proves to be a one-off.
• Management commentary: Guidance on demand, margins and capital allocation for the rest of FY27.
• Sector conditions: Developments in the healthcare digital technology and consulting space that could influence input costs, pricing power or competitive intensity.
• Corporate actions: Any dividend, capex or strategic announcements accompanying the results that signal management's confidence in the outlook.
• Balance sheet health: Debt levels, working capital trends and cash flow generation, which together determine how much flexibility Indegene has to fund future growth.

Download the Univest iOS App or Univest Android App to track quarterly results, live prices and research updates in one place.

Conclusion

The Indegene Q1 results FY27 show consolidated revenue of Rs 1,063 Cr and a net profit of Rs 116 Cr for the quarter ended 30 June 2026. The quarter's profit delivery keeps the near-term earnings narrative broadly intact. As Kunal Singla notes, investors should track the next few quarterly prints and management commentary before drawing firm conclusions, and consult a SEBI registered investment adviser before acting on these results.

FAQs on Indegene Q1 Results FY27

What was Indegene's revenue in Q1 results FY27?

Ans. Indegene's revenue in Q1 results FY27 was Rs 1,063 Cr, rose 39.73% year on year from Rs 760 Cr.

Did Indegene make a profit or loss in Q1 FY27?

Ans. Indegene reported a net profit of Rs 116 Cr in Q1 results FY27 on a consolidated basis for the quarter ended 30 June 2026.

What was Indegene's gross profit in Q1 FY27?

Ans. Indegene's gross profit in Q1 results FY27 was Rs 130 Cr, against Rs 133 Cr in Q1 FY26.

When were the Indegene Q1 results FY27 announced?

Ans. The Indegene Q1 results FY27 were announced on 30 July 2026, covering the quarter ended 30 June 2026.

Did Indegene shares go up or down after the Q1 results FY27?

Ans. Indegene shares traded at Rs 514.7 on 30 July 2026, down 1.70% following the Q1 results FY27.

Were the Indegene Q1 results FY27 consolidated or standalone?

Ans. The Indegene Q1 results FY27 are on a consolidated basis, as reported in the company's exchange filing for the June 2026 quarter.

What should investors watch after Indegene's Q1 results FY27?

Ans. Investors should watch the sequential trend into the September quarter, management commentary, sector-level conditions in the healthcare digital technology and consulting space, and any corporate action announcements.

Are the Indegene Q1 results FY27 a buy signal?

Ans. Quarterly results are a data point, not a recommendation. Investors should assess valuations, earnings quality and their own risk profile, and consult a SEBI registered investment adviser before investing.